insulin aspart

Also found in: Thesaurus, Medical, Encyclopedia, Wikipedia.

insulin as·part

A rapid-acting insulin analog whose amino acid sequence differs from that of human insulin by the substitution of aspartic acid for proline in the B chain, used in the treatment of type 1 and type 2 diabetes.

American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.
Mentioned in ?
References in periodicals archive ?
New data presented at the 44th Annual Conference of the International Society for Pediatric and Adolescent Diabetes showed that the study population receiving Fiasp achieved superior reductions in overall blood sugar levels, compared to the group on conventional insulin aspart, when both treatments were dosed at mealtime.
M2 PHARMA-March 30, 2017-Novo Nordisk announces resubmission of new drug application for fast-acting insulin aspart in the US
Healthcare company Novo Nordisk Canada Inc reported on Monday the launch of Fiasp (insulin aspart) in Canada as a new treatment option for achieving optimal mealtime glucose control in diabetic patients in the country.
The company also started Phase IIIa research on the faster-acting formulation of insulin aspart and moved semaglutide, a once-weekly treatment, into phase III trials.
CHMP's review showed that children with type 1 diabetes, aged two to five, treated with insulin Detemir together with a fast-acting insulin analogue, insulin aspart, had lower all-day and nocturnal hypoglycaemia when compared to those who take human basal insulin.
The "Where Have You Flexed?" contest is open to patients who use Levemir FlexPen (insulin detemir [rDNA origin] injection) NovoLog FlexPen (insulin aspart [rDNA origin] injection) and NovoLog Mix 70/30 FlexPen (70% insulin aspart protamine suspension and 30% insulin aspart injection [rDNA origin]).
They were randomized to one of three supplemental insulin regimens in the first year: prandial insulin aspart (NovoRapid) three times daily, biphasic insulin aspart (NovoMix 30) twice daily, or basal detemir (Levemir) once daily, or twice if needed.
Greater decreases in mean glycated hemoglobin levels were seen in patients who were randomized to either biphasic insulin aspart twice daily or prandial insulin aspart three times daily, compared with basal insulin detemir once daily (or twice daily if needed).
An open-label RCT with 341 patients who were inadequately controlled on metformin compared beginning combination therapy (biphasic insulin aspart 30/70 [Novolog Mix 70/30] and metformin) with switching to insulin alone (biphasic insulin aspart 30/70).